Breakdown | |||||
TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.54T | 2.45T | 2.90T | 2.77T | 2.29T | 2.23T | Gross Profit |
624.35B | 499.69B | 820.93B | 873.86B | 771.20B | 706.76B | EBIT |
-245.87B | -387.43B | -30.98B | 215.00B | 137.12B | 137.52B | EBITDA |
2.74B | -258.31B | 199.08B | 388.68B | 306.28B | 268.52B | Net Income Common Stockholders |
-173.48B | -311.84B | 6.99B | 162.13B | 46.04B | 30.93B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
217.45B | 217.45B | 337.08B | 389.42B | 373.73B | 189.59B | Total Assets |
3.93T | 3.93T | 4.17T | 4.31T | 3.99T | 3.65T | Total Debt |
1.67T | 1.56T | 1.46T | 1.35T | 1.35T | 1.30T | Net Debt |
1.46T | 1.35T | 1.16T | 985.04B | 990.15B | 1.12T | Total Liabilities |
2.77T | 2.77T | 2.68T | 2.61T | 2.51T | 2.26T | Stockholders Equity |
965.75B | 965.75B | 1.17T | 1.22T | 1.02T | 922.34B |
Cash Flow | Free Cash Flow | ||||
81.45B | -204.19B | -31.96B | 64.25B | 253.65B | -14.44B | Operating Cash Flow |
224.39B | -51.32B | 111.62B | 171.72B | 374.46B | 106.01B | Investing Cash Flow |
22.29B | -112.24B | -19.41B | -115.42B | -177.39B | -499.67B | Financing Cash Flow |
-253.54B | 49.25B | -178.50B | -81.39B | -39.97B | 373.54B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $555.02B | 14.26 | 3.96% | 2.16% | 6.51% | ― | |
51 Neutral | $2.01B | -1.11 | -21.16% | 3.67% | 2.69% | -30.65% | |
$9.49B | 10.20 | 7.25% | 3.59% | ― | ― | ||
$4.10B | 28.68 | 2.92% | 2.75% | ― | ― | ||
$7.53B | 25.33 | 2.49% | 4.04% | ― | ― | ||
€3.52B | 13.38 | 18.55% | 4.20% | ― | ― | ||
$63.23B | 18.32 | 11.81% | 2.17% | ― | ― |
Sumitomo Chemical Co., Ltd. has announced a change in its leadership, appointing Keigo Sasaki as the new Representative Director. This decision, aimed at strengthening the company’s management structure, will be finalized at the upcoming General Meeting of Shareholders and subsequent Board of Directors meeting.
The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.
Sumitomo Chemical Co., Ltd. has announced a proposal for partial amendments to its Articles of Incorporation, which will be discussed at the upcoming General Meeting of Shareholders on June 20, 2025. The proposed changes include transitioning to a company with an Audit and Supervisory Committee, establishing new provisions for directors and decision-making processes, and allowing for more flexible resolutions by the Board of Directors. These amendments aim to enhance the company’s governance structure and operational flexibility.
The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.
Sumitomo Chemical Co., Ltd. announced significant impairment losses and finance expenses for the fourth quarter of FY2024. The impairment losses, totaling ¥20,802 million, were primarily due to decreased profitability in their advanced medical solutions and essential materials sectors, as well as the devaluation of patent rights. Additionally, a foreign exchange loss of ¥26,342 million was recorded, impacting the company’s financial results due to fluctuations in foreign currency valuations.
The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.
Sumitomo Chemical Co. reported its consolidated financial results for the fiscal year 2024, highlighting a significant improvement in financial performance compared to the previous year. The company achieved a sales revenue of ¥2,606,281 million, marking a 6.5% increase from FY 2023, and a notable recovery in net income attributable to owners of the parent, which stood at ¥38,591 million. This positive financial outcome reflects the company’s strategic efforts to enhance its operational efficiency and market positioning, benefiting stakeholders and reinforcing its industry standing.
The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.
Sumitomo Chemical Co. reported variances in the non-consolidated financial results of its subsidiaries for fiscal years 2024 and 2023. Sumitomo Pharma Co., Ltd. saw significant improvements in net sales and income due to increased sales in North America and China, alongside reduced expenses. Taoka Chemical Co., Ltd. experienced growth in sales and income driven by higher sales of resin raw materials and cost-cutting measures. The overall impact on Sumitomo Chemical’s consolidated financial forecast is considered immaterial.
The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.
Sumitomo Chemical has revised its financial forecast for the fiscal year ending March 31, 2025, reflecting improved performance across several segments. The company anticipates higher core operating income and net income due to increased sales in North America for its prostate cancer therapeutic agent and higher shipments of display-related materials. These adjustments indicate a positive outlook for the company’s financial health and strategic positioning in its industry.
Sumitomo Chemical Co., Ltd. announced a strategic move involving its subsidiary, Sumitomo Pharma Co., Ltd., which plans to establish a new wholly-owned subsidiary to manage its Asian business. This business will undergo a simplified absorption-type company split, with 60% of the new company’s shares to be transferred to Marubeni Global Pharma Inc. The agreements are expected to strengthen Sumitomo’s financial foundation and leverage Marubeni’s global network for further growth, although the immediate financial impact is deemed immaterial.